These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19695688)

  • 21. Impact of combination chemotherapy with itraconazole on survival of patients with refractory ovarian cancer.
    Tsubamoto H; Sonoda T; Yamasaki M; Inoue K
    Anticancer Res; 2014 May; 34(5):2481-7. PubMed ID: 24778064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients.
    Liutkauskiene S; Janciauskiene R; Jureniene K; Grizas S; Malonyte R; Juozaityte E
    BMC Cancer; 2015 Mar; 15():105. PubMed ID: 25879527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6).
    Wagner U; du Bois A; Pfisterer J; Huober J; Loibl S; Lück HJ; Sehouli J; Gropp M; Stähle A; Schmalfeldt B; Meier W; Jackisch C;
    Gynecol Oncol; 2007 Apr; 105(1):132-7. PubMed ID: 17161453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Compliance to consensus recommendations, surgeon's experience, and introduction of a quality assurance and management program: influence on therapy of early-stage ovarian carcinoma.
    Kommoss S; Harter P; Traut A; Strutas D; Riegler N; Buhrmann C; Gomez R; du Bois A
    Int J Gynecol Cancer; 2009 May; 19(4):787-93. PubMed ID: 19509589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm.
    Bristow RE; Palis BE; Chi DS; Cliby WA
    Gynecol Oncol; 2010 Sep; 118(3):262-7. PubMed ID: 20573392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study.
    Hofstetter G; Concin N; Braicu I; Chekerov R; Sehouli J; Cadron I; Van Gorp T; Trillsch F; Mahner S; Ulmer H; Grimm C; Castillo-Tong DC; Zeillinger R; Zeimet AG; Vergote I
    Gynecol Oncol; 2013 Oct; 131(1):15-20. PubMed ID: 23877013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival and prognostic factors in early-stage epithelial ovarian carcinoma treated with taxane-based adjuvant chemotherapy.
    Skírnisdóttir I; Sorbe B
    Int J Gynecol Cancer; 2007; 17(6):1231-7. PubMed ID: 17425681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome.
    Karam AK; Santillan A; Bristow RE; Giuntoli R; Gardner GJ; Cass I; Karlan BY; Li AJ
    Gynecol Oncol; 2007 Feb; 104(2):377-80. PubMed ID: 17014899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
    Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients.
    Rocconi RP; Matthews KS; Kemper MK; Hoskins KE; Barnes MN
    Gynecol Oncol; 2008 Feb; 108(2):336-41. PubMed ID: 18006047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    N Engl J Med; 1996 Jan; 334(1):1-6. PubMed ID: 7494563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma.
    Eisenhauer EL; Sonoda Y; Levine DA; Abu-Rustum NR; Gemignani ML; Sabbatini PJ; Barakat RR; Chi DS
    Am J Obstet Gynecol; 2008 Feb; 198(2):213.e1-7. PubMed ID: 18226627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
    Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
    Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary.
    Moore KN; Moxley KM; Fader AN; Axtell AE; Rocconi RP; Abaid LN; Cass IA; Rose PG; Leath CA; Rutledge T; Blankenship D; Gold MA
    Gynecol Oncol; 2007 Dec; 107(3):398-403. PubMed ID: 17997146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.